JP2018535972A5 - - Google Patents

Download PDF

Info

Publication number
JP2018535972A5
JP2018535972A5 JP2018522651A JP2018522651A JP2018535972A5 JP 2018535972 A5 JP2018535972 A5 JP 2018535972A5 JP 2018522651 A JP2018522651 A JP 2018522651A JP 2018522651 A JP2018522651 A JP 2018522651A JP 2018535972 A5 JP2018535972 A5 JP 2018535972A5
Authority
JP
Japan
Prior art keywords
amino acid
naturally encoded
encoded amino
antibody
molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018522651A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018535972A (ja
JP6931649B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/060087 external-priority patent/WO2017079272A2/en
Publication of JP2018535972A publication Critical patent/JP2018535972A/ja
Publication of JP2018535972A5 publication Critical patent/JP2018535972A5/ja
Priority to JP2021132397A priority Critical patent/JP7220755B2/ja
Application granted granted Critical
Publication of JP6931649B2 publication Critical patent/JP6931649B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018522651A 2015-11-03 2016-11-02 新規な抗cd3抗体およびその使用 Active JP6931649B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021132397A JP7220755B2 (ja) 2015-11-03 2021-08-16 新規な抗cd3抗体およびその使用

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562250451P 2015-11-03 2015-11-03
US62/250,451 2015-11-03
US201562267086P 2015-12-14 2015-12-14
US62/267,086 2015-12-14
US201662374693P 2016-08-12 2016-08-12
US62/374,693 2016-08-12
PCT/US2016/060087 WO2017079272A2 (en) 2015-11-03 2016-11-02 Anti-cd3-folate conjugates and their uses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021132397A Division JP7220755B2 (ja) 2015-11-03 2021-08-16 新規な抗cd3抗体およびその使用

Publications (3)

Publication Number Publication Date
JP2018535972A JP2018535972A (ja) 2018-12-06
JP2018535972A5 true JP2018535972A5 (enExample) 2019-12-12
JP6931649B2 JP6931649B2 (ja) 2021-09-08

Family

ID=58662682

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018522651A Active JP6931649B2 (ja) 2015-11-03 2016-11-02 新規な抗cd3抗体およびその使用
JP2021132397A Active JP7220755B2 (ja) 2015-11-03 2021-08-16 新規な抗cd3抗体およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021132397A Active JP7220755B2 (ja) 2015-11-03 2021-08-16 新規な抗cd3抗体およびその使用

Country Status (13)

Country Link
US (2) US11851488B2 (enExample)
EP (1) EP3370771A4 (enExample)
JP (2) JP6931649B2 (enExample)
KR (1) KR20180077271A (enExample)
CN (1) CN108348603B (enExample)
AU (1) AU2016349786C1 (enExample)
BR (1) BR112018009004A8 (enExample)
CA (1) CA3002573A1 (enExample)
IL (1) IL258759B2 (enExample)
MX (1) MX2018005232A (enExample)
NZ (1) NZ743049A (enExample)
SG (2) SG11201803211TA (enExample)
WO (1) WO2017079272A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200184381A1 (en) * 2017-11-22 2020-06-11 Geltor, Inc. Methods and systems for engineering collagen
MX2021002301A (es) * 2018-08-28 2021-04-28 Ambrx Inc Bioconjugados de anticuerpo-foliato anti-cd3 y sus usos.
KR102239781B1 (ko) * 2019-04-08 2021-04-13 주식회사 녹십자 Gpnmb 및 cd3에 특이적으로 결합하는 이중특이적 항체 및 이의 용도
US20200392230A1 (en) * 2019-05-14 2020-12-17 Qlb Biotherapeutics Bispecific anti-cd3 x cd20 antibodies and uses thereof
EP3972998A1 (en) 2019-05-21 2022-03-30 Novartis AG Cd19 binding molecules and uses thereof
TWI888487B (zh) * 2020-02-14 2025-07-01 日商協和麒麟股份有限公司 與cd3結合之雙特異性抗體
TWI827807B (zh) * 2020-02-26 2024-01-01 香港商潤俊(中國)有限公司 抗cd3抗體葉酸生物共軛物及其用途
WO2021173889A1 (en) 2020-02-26 2021-09-02 Ambrx, Inc. Uses of anti-cd3 antibody folate bioconjugates
IL300256A (en) 2020-08-25 2023-03-01 Gilead Sciences Inc Multispecific Antigen Binding Molecules Targeting HIV and Methods of Use

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
FR2504010B1 (fr) 1981-04-15 1985-10-25 Sanofi Sa Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
EP0092227B1 (en) 1982-04-19 1988-07-27 Nissan Motor Co., Ltd. Method for controlling reduction ratio of continuously variable transmission with acceleration compensation
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
US4625014A (en) 1984-07-10 1986-11-25 Dana-Farber Cancer Institute, Inc. Cell-delivery agent
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4659839A (en) 1984-10-10 1987-04-21 Mallinckrodt, Inc. Coupling agents for radiolabeled antibody fragments
CA1336076C (en) 1985-01-14 1995-06-27 Alan R. Fritzberg Metal radionuclide labeled proteins for diagnosis and therapy
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
DK0615451T3 (da) 1992-05-26 2006-04-24 Immunex Corp Hidtil ukendt cytokin der binder til CD30
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
EP0904107B1 (en) 1996-03-18 2004-10-20 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
DE69838552T2 (de) 1997-07-14 2008-05-21 Bolder Biotechnology, Inc., Louisville Derivate des wachstumshormons und verwandte proteine
US6451986B1 (en) 1998-06-22 2002-09-17 Immunex Corporation Site specific protein modification
JP2002531067A (ja) 1998-10-30 2002-09-24 ノボザイムス アクティーゼルスカブ 低下したアレルゲン性を有するグリコシル化タンパク質
KR101138643B1 (ko) 2002-05-30 2012-04-26 더 스크립스 리서치 인스티튜트 구리 촉매 작용하에서의 아지드와 아세틸렌과의 리게이션
CN103215227B (zh) * 2003-04-17 2015-09-16 斯克利普斯研究院 扩展真核生物遗传密码
CN102618605B (zh) * 2003-06-18 2015-09-02 斯克利普斯研究院 非天然活性氨基酸遗传密码增加
GB0716160D0 (en) * 2007-08-17 2007-09-26 Biotransformations Ltd Materials and methods for treating cancers which express folate receptors
JP2012034668A (ja) 2010-08-12 2012-02-23 Tohoku Univ ヒト型化抗egfr抗体リジン置換可変領域断片及びその利用
CN107903325B (zh) * 2011-05-16 2021-10-29 埃泰美德(香港)有限公司 多特异性fab融合蛋白及其使用方法
SI2714733T1 (sl) * 2011-05-21 2019-06-28 Macrogenics, Inc. CD3-vezavne molekule sposobne vezave na humani ali ne-humani CD3
WO2013092001A1 (en) 2011-12-19 2013-06-27 Synimmune Gmbh Bispecific antibody molecule
US10968276B2 (en) * 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
MX2016000272A (es) * 2013-07-12 2016-08-03 Zymeworks Inc Construcciones de unión a los antígenos cd19 y cd3 biespecificos.
EP2840091A1 (en) * 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
US10669337B2 (en) * 2014-07-25 2020-06-02 Cytomx Therapeutics, Inc. Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the same
CN108431042A (zh) * 2015-11-02 2018-08-21 詹森药业有限公司 抗-il1rap抗体,结合il1rap和cd3的双特异性抗原结合分子及其用途
BR112020021279A2 (pt) * 2018-04-17 2021-04-13 Invenra Inc. Constructos de anticorpos trispecíficos trivalentes
MX2021002301A (es) * 2018-08-28 2021-04-28 Ambrx Inc Bioconjugados de anticuerpo-foliato anti-cd3 y sus usos.
WO2020168017A1 (en) * 2019-02-12 2020-08-20 Ambrx, Inc. Compositions containing, methods and uses of antibody-tlr agonist conjugates
KR20210142638A (ko) * 2019-02-22 2021-11-25 우한 이지 바이오파마 씨오., 엘티디. Cd3 항원 결합 단편 및 이의 응용

Similar Documents

Publication Publication Date Title
JP2018535972A5 (enExample)
JP2019033743A5 (enExample)
US20240100129A1 (en) Serum Albumin-Binding Fibronectin Type III Domains
ES2885815T3 (es) Nuevo formato biespecífico adecuado para su uso en el cribado de alto rendimiento
CN102906112B (zh) Trail r2-特异性多聚体支架
ES2967739T3 (es) Formato de anticuerpo heterodimérico multiespecífico dirigido al menos a CD3 y a HSA
JP2017529067A5 (enExample)
JP2017529097A5 (enExample)
JP2016536322A5 (enExample)
RU2016151265A (ru) Антитела, направленные на cd127
ES2822431T3 (es) Polipéptidos de unión a IL-17A
JP2013506411A5 (enExample)
RU2015100656A (ru) Способ получения конъюгатов fc-фрагмента антитела, включающих по меньшей мере одну связывающую группировку, которая специфически связывается с мишенью, и их применения
JP2010535032A5 (enExample)
JP2011501951A5 (enExample)
RU2018141360A (ru) Contorsbody - одноцепочечный связывающий мишень агент
JP2013529080A5 (enExample)
JP2017529870A5 (enExample)
JP2017523781A5 (enExample)
JP2008515889A5 (enExample)
JP2017534296A5 (enExample)
JP2019505565A5 (enExample)
Gerling-Driessen et al. Exploiting Oligo (amido amine) backbones for the multivalent presentation of coiled-coil peptides
JP7014727B2 (ja) ポリペプチドライブラリ
ITFI20090006A1 (it) Processo per la produzione di proteine di fusione polivalenti e polispecifiche utilizzando come struttura portante l'uteroglobina e prodotti cosi' ottenuti.